NEWS

Andira Pharmaceuticals Announces Trade Name Change: Matrix3™ Becomes Silvanex™

Vancouver, BC, CANADA January 6, 2025 – Andira Pharmaceuticals is excited to announce the brand name change of its groundbreaking antimicrobial technology from Matrix3™ to Silvanex™. This change marks a significant milestone as we continue to innovate and enhance the efficacy of silver-based antimicrobial solutions.

Silvanex™ antimicrobial technology is a breakthrough for medical infection control, representing a next-generation improved antimicrobial silver with 800% improved efficacy against all major classes of healthcare-associated infection pathogens. The unique triple synergy combination of silver with two cannabinoids in Silvanex™ amplifies its potency against Gram-positive bacteria, Gram-negative bacteria, and fungi, overcoming antimicrobial resistance (AMR) with remarkable success.

As the first of its kind globally, the silver-cannabinoid Silvanex™ formula functions as both an antibacterial and antifungal agent. The amplified potency of this infection control breakthrough offers faster onset of action, and a unique cell-wall active mechanism of action that prevents future resistance from emerging.

Andira’s Founder and CEO, Dana Lambert, Ph.D., commented, “The name Silvanex™ will help anchor the technology as an improved next-generation silver antimicrobial, making it easier for the industry to understand its position in the market, faster and easier, as compared to Matrix3™.”

Silvanex™ antimicrobial technology is positioned for use in all the same commercial applications as standard antimicrobial silver, including but not limited to medical devices (such as wound dressings and catheters), externally-applied drug products for infection control applications such as post-surgical care, medical supplies, surface coatings for high-touch areas, and integration into fabrics, textiles, and other materials prone to microbial contamination, such as fitness equipment.

For more information, please visit our website at www.andira.ca or follow us on LinkedIn for the latest updates.

About Andira Pharmaceuticals

Andira Pharmaceuticals is a cannabinoid-focused biopharmaceutical company developing innovative therapeutics and medical devices to address healthcare-associated infections (HAI) and improve the treatment of cancer.

 

Join us in transforming the future of healthcare with our groundbreaking cannabinoid therapeutics and medical devices.